Abstract：In order to investigate the strategy of diagnosis and treatment for renal cell carcinoma (RCC) with tumor thrombus, Beijing Tumor Thrombus Collaboration Group held the first meeting in Chinese PLA General Hospital. During this meeting, the attending experts have discussed the major hotspots and key issues in the process of diagnosing and treating RCC with tumor thrombus, and reached a consensus. The contents contain tumor thrombus classification system-301 classification, preoperative targeted therapy, postoperative targeted therapy for non-metastatic RCC with tumor thrombus, the strategy and indication of inferior vena cava (IVC) angiography, the indication and strategy of IVC amputation, IVC tumor thrombus with thrombosis and suggested treatment, etc. The present paper summary the expert opinions and related research progress.
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-132. [2] Hatcher PA. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol, 1991,145(1):20-23. [3] Parra J, Drouin SJ, Hupertan V, et al. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: A single-centre experience. EJSO, 2011,37(5):422-428. [4] Haferkamp, A.Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol, 2007,177(5):1703-1708. [5] Kaushik D, Linder BJ, Thompson R, et al. The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. Urology, 2013,82(1):136-141. [6] Tilki D, Nguyen HG, Dall'Era MA, et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol, 2014,66(3):577-583 . [7] Gu L, Wang Z, Chen L, et al. A proposal of post-operative nomogram for overall survival in patients with renal cell carcinoma and venous tumor thrombus. J Surg Oncol, 2017,115(7):905-912 . [8] Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol, 1987,59(5):390-395. [9] Ciancio G, Vaidya A, Savoie M, et al. Management of renal cell carcinoma with level III thrombus in the inferior vena cava. J Urol, 2002,168(4 Pt 1):1374-1377. [10] Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int, 2004,94(1):33-41. [11] Skinner DG, Pfister RF, Colvin R. Extension of renal cell carcinoma into the vena cava: the rationale for aggressive surgical management. J Urol, 1972,107(5):711-716. [12] Fergany AF, Gill IS, Schweizer DK, et al. Laparoscopic radical nephrectomy with level II vena caval thrombectomy: Survival porcine study. J Urol, 2002,168(6):2629-2631. [13] Sundaram CP, Rehman J, Landman J, et al. Hand assisted laparoscopic radical nephrectomy for renal cell carcinoma with inferior vena caval thrombus. J Urol, 2002,168(1):176-179. [14] Abaza R. Initial series of robotic radical nephrectomy with vena caval tumor thrombectomy. Eur Urol, 2011,59(4):652-656. [15] Bansal RK, Tu HY, Drachenberg DA, et al. Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus. Urology, 2014,83(4):812-816. [16] Tang Q, Wang TY, Li XE, et al. Renal cell carcinoma with infrahepatic vena caval tumor thrombus treated with a novel combined retroperitoneal and transperitoneal pure laparoscopic procedure. Urology, 2014,83(5):E9-E10. [17] Abaza R, Shabsigh A, Castle E, et al. Multi-Institutional experience with robotic nephrectomy with inferior vena cava tumor thrombectomy. J Urol, 2016,195(4 Pt 1):865-871. [18] Shao PF, Li J, Qin C, et al. Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma. Eur Urol, 2015,68(1):115-122. [19] Wang B, Li H, Ma X, et al. Robot-assisted Laparoscopic Inferior Vena Cava Thrombectomy: Different Sides Require Different Techniques. Eur Urol, 2016,69(6):1112-1119 . [20] Gu L, Ma X, Gao Y, et al. Robotic versus Open Level I-II Inferior Vena Cava Thrombectomy: A Matched Group Comparative Analysis. J Urol, 2017,198(6):1241-1246 . [21] Marshall FF, Dietrick DD, Baumgartner WA, et al. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol, 1988,139(6):1166-1172. [22] Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol, 2009, 182(3): 881-886. [23] Rini BI, Garcia J, Elson P, et al. The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol, 2012,187(5):1548-1554. [24] Di Silverio F, Sciarra A, Parente U, et al. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int, 2008,80(4):451-453. [25] Cost NG, Delacroix SE, Sleeper JP, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol, 2011,59(6):912-918. [26] Bigot P, Fardoun T, Bernhard JC, et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol, 2014,32(1):109-114. [27] Fukuda H, Kondo T, Takagi T, et al. Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. Int J Clin Oncol, 2017,22(4):767-773. [28] Kirkali Z, Poppel HV. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol, 2007,52(3): 658-662. [29] Pal SK, Haas NB. Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist, 2014,19(8):851-859. [30] Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007,356(2):125-134. [31] Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007,356(2):115-124. [32] Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med, 2016,375(23):2246-2254. [33] Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 2016,387(10032):2008-2016. [34] Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol,2017:JCO2017735324. [35] Bex A, Albiges L, Ljungberg B, et al. Updated European association of urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur Urol, 2017,71(5):719-722 . [36] Gu L, Li H, Chen L, et al. Postoperative adjuvant sorafenib or sunitinib for nonmetastatic renal cell carcinoma with venous tumor thrombus:a prospective cohort study. Transl Oncol, 2017,10(6):949-955. [37] Hallscheidt PJ, Fink C, Haferkamp A, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr, 2005,29(1):64-68. [38] Erden A. Budd-Chiari syndrome:a review of imaging findings. Eur J Radiol, 2007,61(1):44-56. [39] Goldfarb DA, Novick AC, Lorig R, et al. Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venacavography and computerized tomography scanning. J Urol, 1990,144(5):1100-1103. [40] Selby JB Jr, Pryor JL, Tegtmeyer CJ, et al. Inferior vena caval invasion by renal cell carcinoma: false positive diagnosis by venacavography. J Urol, 1990,143(3):464-467. [41] Blute ML, Boorjian SA, Leibovich BC, et al. Results of inferior vena caval interruption by Greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol, 2007,178(2):440-444. [42] Caso J, Seigne J, Back M, et al. Circumferential resection of the inferior vena cava for primary and recurrent malignant tumors. J Urol, 2009,182(3):887-893. [43] Psutka SP, Leibovich BC. Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. Ther Adv Urol, 2015,7(4):216-229. [44] Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol, 2007,25(34):5490-5505. [45] Woodruff DY, Van Veldhuizen P, Muehlebach G, et al. The perioperative management of an inferior vena caval tumor thrombus in patients with renal cell carcinoma. Urol Oncol, 2013,31(5):517-521. [46] Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev, 2010,17(2):Cd006212.
